New Obesity Drug Combo Trial Has Begun
Researchers are testing if adding a new investigational drug to tirzepatide improves weight loss for people with obesity.
Updated on Sept. 23, 2026 in Weight Loss
Live Poll
Do you trust that newer obesity treatments will prioritize preserving muscle mass over simple weight loss?
Wave Life Sciences has initiated a Phase 2a clinical trial evaluating the combination of their investigational GalNAc-siRNA drug, WVE-007, with the common obesity treatment tirzepatide. The study enrolls participants living with obesity and type 2 diabetes.
Why it matters
This trial aims to see if adding WVE-007 can boost fat loss while better preserving muscle mass than current incretin medications alone. If successful, it could provide a new approach for managing weight and metabolic health.
The Phase 2a trial is a placebo-controlled study with a 3:1 ratio involving adults with obesity and type 2 diabetes with a BMI between 35 and 50 kg/m2. Researchers are currently evaluating the safety and efficacy of 240 mg and 400 mg doses of WVE-007 administered alongside tirzepatide.
The players
Wave Life Sciences
A Cambridge-based biotechnology company developing nucleic acid-based therapies for genetic diseases, obesity, and cardiovascular conditions.
The details
WVE-007 is an investigational GalNAc-siRNA designed to influence biological pathways associated with metabolic health. By combining this treatment with weekly doses of tirzepatide, investigators are testing if the two therapies produce synergistic results. Preclinical data suggests that this combination may enhance fat loss while better preserving muscle mass than using incretins like tirzepatide as a monotherapy.
Timeline
Wave Life Sciences presented preclinical data at ObesityWeek 2025.
The Phase 2a clinical trial was initiated on September 23, 2026.
A post-incretin maintenance therapy trial is planned for the second half of 2026.
Health Landscape
This trial is part of the INLIGHT clinical program, which systematically assesses WVE-007 as both a monotherapy and a combination treatment. It represents the latest attempt to evolve weight-loss care beyond current incretin-only standards by targeting fat loss and muscle preservation.
This development is in the research phase and is not yet available for clinical use. Patients with obesity and type 2 diabetes interested in upcoming options should discuss the current standards of care with their physician.
The takeaway
This trial investigates whether combining WVE-007 with tirzepatide can improve weight loss outcomes for those managing obesity and type 2 diabetes. If you are currently on an incretin therapy, keep following updates on how clinical trials are working to improve muscle-to-fat ratios.
What happens next
Wave Life Sciences plans to initiate a clinical trial for post-incretin maintenance therapy in the second half of 2026.
Further reading
For more on evolving approaches to weight management, visit our Weight Loss section.
Live Poll
Do you trust that newer obesity treatments will prioritize preserving muscle mass over simple weight loss?
